Bayer, a notable entity in the bio-tech market, has been experiencing significant volatility in its stock performance over some time. The company shares have dipped by
7% following the U.S court's decision to review the Monsanto case. Unexpectedly, the company shares gained upward momentum as Bayer won the Roundup cancer claims in the U.S., boosting shares significantly. However,
shares plummeted again when the U.S. court decided to revisit the PCB case. On the brighter side, Bayer CropScience stock showcased a promising trend, outshining its sector by 1.45%. Major Bayer investor,
Harris, threw his weight behind the CEO's focus on internal restructuring. Bayer also reported uplifting safety information concerning a Parkinson's Disease Drug. Unfortunately, the
dividend was trimmed to manage the growing debt burden, causing shares to
slip. The company presents encouraging results from a late-stage cardiovascular study while successfully entering
mid-stage study for a Chronic Kidney Disease Drug. Bayer CropScience stock, however, saw a 3.12% dip and was graded 'Hold' by MarketsMOJO. Finally, experts caution investors to be prepared for a painful restructuring as Bayer addresses pipeline progress amid numerous challenges.
BAYER Stocks News Analytics from Wed, 08 Nov 2023 08:00:00 GMT to Thu, 31 Oct 2024 06:08:52 GMT -
Rating -5
- Innovation -3
- Information 7
- Rumor -4
